A tumor-targeting pharmaceutical composition mediated by somatostatin receptor
A somatostatin receptor and tumor-targeting technology, applied in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., can solve the problems of increasing curative effect, reducing drug diffusion, hindering liposome fusion and phagocytosis, and achieving simple production Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0059] Octreotide (OCT)-modified long-circulating liposome OCT-L[CD] simultaneously loaded with CA-4 and doxorubicin
[0060] The formulations of the liposomes were: EPC:CHOL:DSPE-PEG:CA-4 (25:1.28:6.24:2) (unit: mg). Accurately weigh the prescribed amount of EPC, CHOL, DSPE-PEG, DSPE-PEG-OCT (2% molar ratio) and CA-4, put them in a pear-shaped bottle, and add an appropriate amount of chloroform to dissolve. Rotary evaporation under reduced pressure at 37°C formed a uniform transparent film. Add 123mM ammonium sulfate solution, and sonicate in a water bath until blue opalescence appears. A polycarbonate film of 200 nm was extruded 5 times. Pass the prepared liposomes through a Sephadex G50 column, elute with PBS buffer (pH7.4) as the mobile phase, collect the liposome fraction, heat the collected liposomes in a water bath at 40°C, add Adriamycin Incubate the plain powder for 20 minutes and shake it frequently to obtain this product.
Embodiment 2
[0062] Basic physicochemical properties of octreotide (OCT)-modified long-circulating liposome OCT-L[CD] loaded with CA-4 and doxorubicin
[0063] The basic physical and chemical properties of the long-circulating liposome L[CD] and OCT-L[CD] prepared by the present invention, which simultaneously entrap CA-4 and doxorubicin, are compared in Table 1:
[0064] preparation Average particle size (nm) PDI Surface potential (mv)
[0065] L(D) 88.65 0.237 -4.916 OCT-L(D) 86.87 0.169 -5.189 L(CD) 92.70 0.232 -2.198 OCT-L (CD) 91.43 0.199 -4.911
Embodiment 3
[0067] In vitro tumor cell (NCI-H446) growth inhibition test of OCT-modified long-circulating liposome OCT-L[D] loaded with doxorubicin. The results of the study showed that the cytotoxic effect of octreotide OCT-modified liposomes was more obvious than that of non-targeted modified liposomes, which also indicated that the tumor cell-targeting effect of octreotide-modified liposomes could significantly enhance the antitumor drug effect. cellular uptake. For specific results, see figure 1 .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com